Danske Bank A S Has $82.48 Million Stock Holdings in Boston Scientific Corporation $BSX

Key Points

• Danske Bank A/S reduced its position in Boston Scientific by 10.6% in Q4, selling 103,023 shares and now holding 865,062 shares worth about $82.48 million, while institutional investors collectively own roughly 89.07% of BSX.
• Boston Scientific slightly beat Q1 estimates with $0.80 EPS on $5.20 billion revenue and issued guidance of Q2 EPS $0.820–0.840 and FY2026 EPS 3.340–3.410, and the stock carries a MarketBeat consensus rating of Moderate Buy with a $93.91 target.
• Key near‑term catalysts include positive clinical data and new hedge‑fund interest, but the stock faces headwinds from a recent CEO share sale, class‑action litigation over electrophysiology disclosures, and several analyst downgrades trimming price targets.

Danske Bank A S decreased its position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 10.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 865,062 shares of the medical equipment provider's stock after selling 103,023 shares during the period. Danske Bank A S owned about 0.06% of Boston Scientific worth $82,484,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in shares of Boston Scientific by 0.8% in the 3rd quarter. Vanguard Group Inc. now owns 138,249,447 shares of the medical equipment provider's stock worth $13,497,294,000 after acquiring an additional 1,115,337 shares in the last quarter. Rathbones Group PLC raised its position in shares of Boston Scientific by 20.9% in the 4th quarter. Rathbones Group PLC now owns 2,759,657 shares of the medical equipment provider's stock worth $263,133,000 after acquiring an additional 477,680 shares in the last quarter. Synergy Asset Management LLC increased its position in Boston Scientific by 3,493.0% in the 3rd quarter. Synergy Asset Management LLC now owns 493,323 shares of the medical equipment provider's stock valued at $48,297,000 after buying an additional 479,593 shares in the last quarter. Gladstone Institutional Advisory LLC increased its position in Boston Scientific by 39.5% in the 3rd quarter. Gladstone Institutional Advisory LLC now owns 51,884 shares of the medical equipment provider's stock valued at $5,065,000 after buying an additional 14,700 shares in the last quarter. Finally, Kepler Cheuvreux Suisse SA bought a new stake in Boston Scientific in the 3rd quarter valued at about $26,955,000. Institutional investors and hedge funds own 89.07% of the company's stock.

Wall Street Analysts Forecast Growth

BSX has been the subject of a number of research analyst reports. Robert W. Baird decreased their target price on Boston Scientific from $86.00 to $78.00 and set an "outperform" rating for the company in a research report on Thursday, April 23rd. Weiss Ratings lowered Boston Scientific from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Wednesday, February 4th. Morgan Stanley decreased their target price on Boston Scientific from $130.00 to $118.00 and set an "overweight" rating for the company in a research report on Thursday, February 5th. Jefferies Financial Group decreased their target price on Boston Scientific from $110.00 to $100.00 and set a "buy" rating for the company in a research report on Wednesday, April 22nd. Finally, Evercore decreased their target price on Boston Scientific from $112.00 to $96.00 and set an "outperform" rating for the company in a research report on Thursday, February 5th. One analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and three have given a Hold rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $93.91.

Boston Scientific Price Performance

BSX stock opened at $57.69 on Friday. The company has a market capitalization of $85.74 billion, a P/E ratio of 24.14, a price-to-earnings-growth ratio of 1.05 and a beta of 0.78. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62. Boston Scientific Corporation has a 52-week low of $56.05 and a 52-week high of $109.50. The business has a 50-day simple moving average of $67.06 and a two-hundred day simple moving average of $84.72.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.79 by $0.01. The business had revenue of $5.20 billion during the quarter, compared to the consensus estimate of $5.19 billion. Boston Scientific had a return on equity of 19.68% and a net margin of 17.29%.The company's quarterly revenue was up 11.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Research analysts expect that Boston Scientific Corporation will post 3.38 EPS for the current fiscal year.

Insider Transactions at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of Boston Scientific stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the transaction, the chief executive officer owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. The trade was a 10.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.34% of the company's stock.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: New clinical data and procedure adoption: A Reuters note highlighted that a procedure using a Boston Scientific device outperformed drug therapy for a heart‑rhythm indication, supporting device demand and reimbursement relevance. This is a clear product/market tailwind if adoption continues. Procedure using Boston Scientific device tops medication
• Positive Sentiment: Supportive TV commentary: Jim Cramer said he thinks Boston Scientific "can come back," a sentiment that can boost retail interest and short‑term buying flows. Jim Cramer on Boston Scientific
• Positive Sentiment: Institutional buying signal: Lone Pine Capital (Stephen Mandel) opened a new position, signaling selective hedge‑fund interest in BSX. Large manager activity can be supportive for the stock if it continues. Stephen Mandel opens new position
• Neutral Sentiment: Investor attention piece: Zacks flagged BSX as drawing investor attention, a sign of increased search/interest but not necessarily directional news. Monitor volume and follow‑through. Zacks: BSX attracting investor attention
• Neutral Sentiment: Ticker confusion: A GlobeNewswire item about Belo Sun TSX: BSX appears in feeds — note this is a different company and unrelated to Boston Scientific NYSE: BSX. Don’t conflate the two. Belo Sun Provides Update (unrelated ticker)
• Neutral Sentiment: Market commentary roundup: Aggregated articles (MSN/Yahoo) are weighing bullish vs bearish views; these are useful for sentiment tracking but contain no single material disclosure. MSN: Wall Street bullish or bearish?
• Negative Sentiment: Class‑action filings and lead‑plaintiff deadline (May 4): Multiple law firms and plaintiff notices allege disclosure issues around U.S. electrophysiology sales and invite claims—this increases legal overhang and potential settlement risk. Monitor filings and reserve/expense guidance. Securities fraud lawsuit alert
• Negative Sentiment: Analyst downgrades and lower targets: Daiwa cut BSX to "hold" and at least one outlet reports an ~11% cut to the price target — these reduce near‑term analyst support and can pressure sentiment. Daiwa downgrade / analyst action
• Negative Sentiment: Fund selling and estimate cuts: Polen Capital disclosed it sold its stake citing competition concerns, and Erste Group trimmed FY2026/27 EPS forecasts — both items point to investor wariness on competitive pressure and margin/earnings outlook. Polen sold stake

About Boston Scientific

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.